Skip to main content

Advertisement

Log in

The cost effectiveness of Botox in Italian patients with chronic migraine

  • SYMPOSIUM Botulinum toxin in clinical practice
  • Published:
Neurological Sciences Aims and scope Submit manuscript

Abstract

Migraine is a primary headache which World Health Organization ranks in 19th place in the list of disabling diseases. In Europe, in 2004, the total costs for migraine were quantified by Stovner and Berg, Eur J Neurol, 12(s1) (2005) at €27 billion. The objective of this study is to provide an estimate of the incremental cost-effectiveness ratio (ICER) of the treatment of chronic migraine with Botox compared to treatment with placebo in the perspective of the Italian National Health Service and society. To do this we studied the disease progression in a cohort of 688 individuals (patients enrolled in the study PREEMPT) via the application of a Markov model. Over a period of 2 years, the total costs of the experimental arm of the model amounted to €3,274 compared with a gain of 1.34 QALYs. In contrast, the costs of the control arm amounted to €2,395 with a gain of 1.24 QALYs. It follows that the incremental costs amounted to €889 compared to an incremental gain of 0.09 QALYs in favor of the experimental arm. The relationship between costs and incremental QALYs generated an ICER of €9,407/QALY. The incremental cost-effectiveness ratio, therefore, is favorable compared to the value usually considered by NICE as a threshold limit for reimbursement which ranges between €20,000 and €40,000/QALY.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. World Health Organization (2004) http://www.who.int/healthinfo/global_burden_disease/estimates_regional/en/index.html.WHO, Geneva

  2. Natoli JL, Manack A, Dean B et al (2009) Global prevalence of chronic migraine: systematic review. Cephalalgia. doi:10.1111/j.1468-2982.2009.01941

    Google Scholar 

  3. Berg J, Stovner LJ (2005) Cost of migraine and other headaches in Europe. Eur J Neurol 12(s1):59–62

    Article  PubMed  Google Scholar 

  4. Dodick DW, Turkel CC, DeGryse RE, et al, on behalf of the PREEMPT Chronic Migraine Study Group (2010) OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 50:921–936

  5. Gillard PJ, Devine B, Varon SF, Sean LL, Sullivan D (2012) Mapping from disease-specific measures to health-state utility values in individuals with migraine. Value Health 15(3):485–494

    Article  PubMed  Google Scholar 

  6. Decreto Ministeriale del 12 settembre 2006. Ricognizione e primo aggiornamento delle tariffe massime per la remunerazione delle prestazioni sanitarie. Gazzetta Ufficiale n. 289 del 13 dicembre 2006

  7. Ministero della Salute (2007) Pronto Soccorso e sistema 118. Progetto Mattoni SSN

  8. Pugliatti M, Sobocki Patrik, Beghi Ettore, Pini Stefano, Cassano Giovanni B, Altamura ACarlo, Pozzoli Sara, Rosati Giulio (2008) Cost of disorders of the brain in Italy. Neurol Sci 29:99–107

    Article  PubMed  Google Scholar 

  9. ISTAT (2008) la struttura del costo del lavoro in Italia

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to M. Ruggeri.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ruggeri, M. The cost effectiveness of Botox in Italian patients with chronic migraine. Neurol Sci 35 (Suppl 1), 45–47 (2014). https://doi.org/10.1007/s10072-014-1741-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10072-014-1741-5

Keywords

Navigation